AMG 655

Vladimir Beljanski

doi:10.1016/B978-008055232-3.64515-5

AMG 655

Vladimir Beljanski

Research output: Chapter in Book/Report/Conference proceeding › Chapter

Abstract

AMG 655 is a fully human monoclonal agonist antibody directed against the extracellular domain of human death receptor 5 (DR5). TRAIL (tumor necrosis factor-related apoptosis inducing ligand) is the natural ligand for DR5 and is a member of the tumor necrosis super-family of cytokines that selectively induces apoptosis in cancer cells by binding to DR4 and DR5. DR4 and DR5 are present on most tumor cells. AMG 655 mimics the activity of native TRAIL, binding to and activating DR5 (TRAIL receptor 2; TR-2), thereby activating .... . © 2010

Original language	English
Title of host publication	xPharm
Subtitle of host publication	The Comprehensive Pharmacology Reference
Editors	S.J. Enna, David B. Bylund
Publisher	Elsevier Inc.
Pages	1-3
Number of pages	3
ISBN (Print)	9780080552323
DOIs	https://doi.org/10.1016/B978-008055232-3.64515-5
State	Published - 2010
Externally published	Yes

ASJC Scopus Subject Areas

General Pharmacology, Toxicology and Pharmaceutics

Disciplines

Medicine and Health Sciences

Access to Document

10.1016/B978-008055232-3.64515-5

Cite this

@inbook{968d95f162fa42f3a36b8b30e9e08682,

title = "AMG 655",

abstract = "AMG 655 is a fully human monoclonal agonist antibody directed against the extracellular domain of human death receptor 5 (DR5). TRAIL (tumor necrosis factor-related apoptosis inducing ligand) is the natural ligand for DR5 and is a member of the tumor necrosis super-family of cytokines that selectively induces apoptosis in cancer cells by binding to DR4 and DR5. DR4 and DR5 are present on most tumor cells. AMG 655 mimics the activity of native TRAIL, binding to and activating DR5 (TRAIL receptor 2; TR-2), thereby activating .... . {\textcopyright} 2010",

author = "Vladimir Beljanski",

year = "2010",

doi = "10.1016/B978-008055232-3.64515-5",

language = "English",

isbn = "9780080552323",

pages = "1--3",

editor = "S.J. Enna and Bylund, \{David B. \}",

booktitle = "xPharm",

publisher = "Elsevier Inc.",

address = "United States",

}

TY - CHAP

T1 - AMG 655

AU - Beljanski, Vladimir

PY - 2010

Y1 - 2010

N2 - AMG 655 is a fully human monoclonal agonist antibody directed against the extracellular domain of human death receptor 5 (DR5). TRAIL (tumor necrosis factor-related apoptosis inducing ligand) is the natural ligand for DR5 and is a member of the tumor necrosis super-family of cytokines that selectively induces apoptosis in cancer cells by binding to DR4 and DR5. DR4 and DR5 are present on most tumor cells. AMG 655 mimics the activity of native TRAIL, binding to and activating DR5 (TRAIL receptor 2; TR-2), thereby activating .... . © 2010

AB - AMG 655 is a fully human monoclonal agonist antibody directed against the extracellular domain of human death receptor 5 (DR5). TRAIL (tumor necrosis factor-related apoptosis inducing ligand) is the natural ligand for DR5 and is a member of the tumor necrosis super-family of cytokines that selectively induces apoptosis in cancer cells by binding to DR4 and DR5. DR4 and DR5 are present on most tumor cells. AMG 655 mimics the activity of native TRAIL, binding to and activating DR5 (TRAIL receptor 2; TR-2), thereby activating .... . © 2010

UR - https://www.scopus.com/pages/publications/84884070816

UR - https://www.scopus.com/pages/publications/84884070816#tab=citedBy

U2 - 10.1016/B978-008055232-3.64515-5

DO - 10.1016/B978-008055232-3.64515-5

M3 - Chapter

AN - SCOPUS:84884070816

SN - 9780080552323

SP - 1

EP - 3

BT - xPharm

A2 - Enna, S.J.

A2 - Bylund, David B.

PB - Elsevier Inc.

ER -

AMG 655

Abstract

ASJC Scopus Subject Areas

Disciplines

Access to Document

Other files and links

Fingerprint

Bendamustine

Cediranib

CPX-351

Cite this